Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nektar Therapeutics ( (NKTR) ) has provided an update.
On February 11, 2026, Nektar Therapeutics priced an upsized underwritten public offering of common stock and pre-funded warrants expected to raise about $400 million in gross proceeds and approximately $432 million in estimated net proceeds after underwriting discounts and expenses, following full exercise on February 12 of underwriters’ 30-day option for additional shares, with closing anticipated on February 13, 2026. All securities are being sold by the company under an effective shelf registration, and Nektar plans to use the capital for general corporate purposes including research and development, Phase 3 development for rezpegaldesleukin, and manufacturing to advance its immunotherapy pipeline, strengthening its funding position for late-stage clinical programs.
The most recent analyst rating on (NKTR) stock is a Buy with a $151.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
Nektar Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and high leverage. Despite technical indicators suggesting bearish momentum, the company’s strong cash position and promising clinical trial results for REZPEG provide some optimism. The recent corporate events and positive earnings call sentiment contribute positively, but the financial challenges remain a significant concern.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company headquartered in San Francisco that develops treatments targeting underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a first-in-class regulatory T cell stimulator in Phase 2b trials for atopic dermatitis and alopecia areata and a Phase 2 trial in Type 1 diabetes, alongside a pipeline of preclinical TNFR2 antibody, bispecific programs NKTR-0165 and NKTR-0166, NKTR-422, and oncology candidate NKTR-255 being studied with partners in several cancer trials.
On February 11, 2026, Nektar Therapeutics priced an upsized underwritten public offering of common stock and pre-funded warrants expected to raise about $400 million in gross proceeds and approximately $432 million in estimated net proceeds after underwriting discounts and expenses, following full exercise on February 12 of underwriters’ 30-day option for additional shares, with closing anticipated on February 13, 2026. All securities are being sold by the company under an effective shelf registration, and Nektar plans to use the capital for general corporate purposes including research and development, Phase 3 development for rezpegaldesleukin, and manufacturing to advance its immunotherapy pipeline, strengthening its funding position for late-stage clinical programs.
Nektar priced an upsized February 2026 equity offering expected to raise about $400 million gross.
The company will use proceeds to fund R&D, late-stage trials and manufacturing, bolstering its immunotherapy pipeline financing.
Average Trading Volume: 966,437
Technical Sentiment Signal: Buy
Current Market Cap: $1.35B
See more insights into NKTR stock on TipRanks’ Stock Analysis page.